Identify and diagnose patients with hereditary or non-hereditary PHEO/PGL based on measurements of metanephrines and 3-methoxytyramine. Improve ability to identify patients with PHEO/PGL based on recently redefined clinical signs
and symptoms.
Properly select the appropriate anatomic/functional imaging modality (e.g., positron emission tomography /PET/)
when localizing hereditary or non-hereditary PHEO/PGL.
Determine the appropriate adrenoceptor or other blockade needed in patients with catecholamine-producing PHEO/PGL.
